alexa SYN-004 (ribaxamase), An Orally Administered β-lactamase For Prevention Of Antibiotic-mediated Dysbiosis Of The Gut Microbiome And Clostridium Difficile Infection In Patients Receiving Intravenous β-lactam Antibiotics
ISSN: 2157-7609

Journal of Drug Metabolism & Toxicology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd World Congress and Exhibition on Antibiotics and Antibiotic Resistance
July 31-August 01, 2017 | Milan, Italy

John F Kokai-Kun
Synthetic Biologics, Inc., USA
Posters & Accepted Abstracts: J Drug Metab Toxicol
DOI: 10.4172/2157-7609-C1-009
Abstract
SYN-004 (ribaxamase) is an orally administered β-lactamase to be given with IV β-lactam antibiotics. Ribaxamase remains localized in the intestine to degrade excreted β-lactam antibiotics which should protect the gut microbiome from disruption thus preventing deleterious effects including, Clostridium Difficile Infection (CDI), and colonization by opportunistic pathogens and emergence of antibiotic resistance in the gut. Ribaxamase was well tolerated in phase 1 studies and efficiently degraded ceftriaxone excreted into the human intestine in Phase 2a studies, where it did not alter the plasma pharmacokinetics of the ceftriaxone. A multinational phase 2b, double-blind, placebo-controlled, study was conducted to determine whether ribaxamase could prevent CDI with additional endpoints for antibiotic-associated diarrhea, colonization by antibiotic-resistant pathogens, changes in the gut micro biome and emergence of antibiotic resistance in the gut. The 412 patient ITT population, enriched for higher risk for CDI, were admitted to the hospital for ≥5 days of IV ceftriaxone for treatment of a lower respiratory tract infection. Patients were randomized 1:1 to receive ribaxamase or placebo during treatment and for 72 h after. Fecal samples were collected at pre-specified points for determination of colonization by opportunistic pathogens and to examine changes in the gut microbiome. Patients were monitored for 6 weeks for CDI (diarrhea plus the presence of C. difficile toxin as determined by the local clinical laboratory). The study was powered at 80% for the reduction in CDI with 1-sided alpha=0.05. The study met its primary endpoint with a 71.4% relative risk reduction in CDI (1-sided p=0.0454), a statistically significant 43.9% relative risk reduction in new colonization by vancomycin resistant enterococci (1-sided p=0.0002) and significant protection of the gut microbiome in the ribaxamase group as compared with the placebo group. These data are consistent with ribaxamase maintaining the balance of the gut microbiome and thereby preventing opportunistic infections like CDI.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords